^
    Back
    Association details:
    Biomarker:ID3 underexpression
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers

    Published date:
    11/06/2019
    Excerpt:
    ID3 expression was decreased at matched relapse samples (p = 0.0001), supporting the presence of the resistance circuit we identified above.
    DOI:
    10.1182/blood-2019-131336